These services may or may not be covered by your HealthPartners plan. Please see your plan documents for your specific coverage information. If there is a difference between this general information and your plan documents, your plan documents will be used to determine your coverage.
Prior Authorization is required for weight loss surgery.
This policy applies only to initial weight loss surgery procedures. Refer to the Weight Loss Surgery Re-operations- Iowa policy for information and coverage criteria for revisions or additional weight loss surgeries.
We encourage members to check with Member Services regarding their health plan benefits for weight loss surgery as well as any provider network limitations which may impact coverage.
- A member must have a documented Body Mass Index (BMI) equal to or greater than 40 or a documented BMI greater than 35 with associated health conditions that do not respond to medical management. Associated health conditions for the purpose of this topic are defined as:
- High blood pressure that is consistently greater than 140/90 on multiple, separate dates despite treatment that has followed standard treatment recommendations of multiple medications, alone and/or in combination, for amounts of time that are generally considered adequate to see treatment success with demonstrated patient compliance to the prescribed treatments; or
- Dyslipidemia with cholesterol LDL consistently greater than or equal to 130 mg/dl separate dates despite treatment that has followed standard treatment recommendations of multiple medications, alone and/or in combination, for amounts of time that are generally considered adequate to see treatment success with demonstrated patient compliance to the prescribed treatments; or
- Clinically significant obstructive sleep apnea (OSA) that has not responded to medical management, confirmed on polysomnography with an apnea-hypopnea index (AHI) or Respiratory Disturbance Index (RDI) equal to or > 30; or
- Diabetes with glycosylated hemoglobin level (HbA1c) that is greater than or equal to 7 on multiple, separate dates, treatment that has followed standard treatment recommendations of multiple medications, alone and/or in combination, for amounts of time that are generally considered adequate to see treatment success with demonstrated patient compliance to the prescribed treatments; or
- Pseudotumor cerebri (a condition in which the pressure around the brain increases, causing headaches and vision problems) not responding to optimal medical management.
- Documentation of an evaluation by a mental health professional which addresses the following:
- The need for any active therapeutic interventions for mental health issues and a plan on how these issues will be addressed;
- The ability of the member to participate in:
- Close nutritional monitoring during rapid weight loss, and
- Long term lifestyle changes;
Weight Loss Surgery Procedures that are eligible for coverage when the above criteria are met. See Definitions section below for an explanation of these procedures:
- Roux-en-Y Gastric Bypass (RYGBP)
- Biliopancreatic diversion with duodenal switch (BPD/DS)
- Sleeve gastrectomy
- Vertical gastric banding (VGB)
- FDA-approved adjustable gastric banding. Examples of FDA approved devices used for adjustable gastric banding include but are not limited to: LAP-BAND, Realize™ Personalized Banding Solution, Swedish adjustable gastric banding (SAGB), etc.
Weight Loss Surgery Procedures that are not eligible for coverage despite the above criteria being met. The following weight loss procedures are considered investigational. There is insufficient reliable evidence in the form of high-quality, peer-reviewed medical literature to establish the safety and efficacy of these treatments or their effect on health care outcomes. These procedures include but are not limited to:
- The laparoscopic loop or “Mini-Gastric Bypass”
- Intragastric balloon procedures
- Implantable gastric stimulator
- Endoluminal procedures, including but not limited to:
- ROSE procedure- restorative obesity surgery-endoluminal
- Transoral gastroplasty
- Vagal Blocking for Obesity Control (VBLOC)
Indications that are not covered
- Any weight loss/bariatric surgery procedure to treat co-morbidities caused by or exacerbated by obesity unless in accordance with the criteria listed above is considered investigational. There is insufficient published evidence to support bariatric surgery as a definitive treatment for obesity associated diseases. These types of procedures will frequently improve symptoms of diabetes, gastroesophageal reflux disease (GERD), osteoarthritis, obstructive sleep apnea (OSA), etc. However, the primary purpose of bariatric surgery is to achieve weight loss.
- Weight loss surgery in a member with a BMI less than 35 is considered cosmetic
Body Mass Index (BMI) is measure of body fat based on height and weight that applies to both adult men and women. Please see related content at right for link to calculate your BMI.
Obesity is defined as a Body Mass Index (BMI) greater than or equal to 30. Obesity is divided into three classifications according to the BMI:
- Class I - BMI 30.0 to 34.9.
- Class II - BMI 35.0 to 39.9.
- Class III - BMI 40 and above.
Obesity is a chronic condition that develops from an interaction of genetics and the environment. Because of these multiple factors, weight loss surgery is not considered to be the first or only treatment for obesity. Treatment requires comprehensive medical and behavioral management. Weight loss and weight control programs use multiple interventions and strategies, including individualized dietary therapy, physical activity, life-style/behavior therapy and surgery. Weight loss surgery is reserved for a limited number of adults whose obesity is:
- Class II and efforts at combined therapies of diet, exercise, and behavioral management have failed and other medical condition(s) existing simultaneously and usually independently of the severe obesity (co-morbidities).
- Class III and efforts at combined therapies of diet, exercise, and behavioral management have failed and are at high risk for obesity-associated co-morbidity or death (mortality).
Weight loss surgery is intended to provide weight loss sufficient to reduce mortality risk and improve medical conditions when less invasive methods of weight loss have failed.
Weight loss surgery is not an alternative to a diet and exercise management program. An integrated program such as HealthPartners’ Weight loss surgery phone course must be in place to provide guidance on diet, physical activity, and behavioral and social support both prior to and after the surgery. Weight loss surgery is a weight loss intervention option for well-informed, motivated individuals with an acceptable operative risk.
Descriptions of bariatric surgery procedures:
Roux-en-Y Gastric Bypass (RYGBP) 43644, 43846
The RYGBP works via restriction and malabsorption. . Reduction of the stomach to a small gastric pouch (30 cc) results in feelings of satiety following even small meals. This small pouch is connected to a segment of the jejunum, bypassing the duodenum and very proximal small intestine, thereby reducing absorption. RYGBP procedures can be open or laparoscopic.
Biliopancreatic Diversion with Duodenal Switch (BPD/DS) 43845
BPD works via restriction and malabsorption. . The stomach is partially resected, but the remaining capacity is generous compared to that achieved with RYGBP. As such, members eat relatively normal-sized meals and do not need to restrict intake radically, since the most proximal areas of the small intestine (i.e., the duodenum and jejunum) are bypassed, and substantial malabsorption occurs. The partial BPD with duodenal switch is a variant of the BPD procedure. It involves resection of the greater curvature of the stomach, preservation of the pyloric sphincter, and transection of the duodenum above the ampulla of Vater with a duodeno-ileal anastamosis and a lower ileo-ileal anastamosis. BPD/DS procedures can be open or laparoscopic.
Sleeve Gastrectomy 43775
Sleeve gastrectomy is a 70%-80% greater curvature gastrectomy (sleeve resection of the stomach) with continuity of the gastric lesser curve being maintained while simultaneously reducing stomach volume. It may be the first step in a two-stage procedure when performing RYGBP. Sleeve gastrectomy procedures can be open or laparoscopic.
Vertical Gastric Banding (VGB) 43842
VBG works via restriction only. . The upper part of the stomach is stapled, creating a narrow gastric inlet or pouch that remains connected with the remainder of the stomach. In addition, a non-adjustable band is placed around this new inlet in an attempt to prevent future enlargement of the stoma (opening). As a result, members experience a sense of fullness after eating small meals. Weight loss from this procedure results entirely from eating less.
Adjustable Gastric Banding (AGB) 43770-43774; 43886-43888; S2083
AGB works via restriction only. A band creating a gastric pouch with a capacity of approximately 15 to 30 cc’s encircles the uppermost portion of the stomach. The band is an inflatable doughnut-shaped balloon, the diameter of which can be adjusted in the clinic by adding or removing saline via a port that is positioned beneath the skin. The bands are adjustable, allowing the size of the gastric outlet to be modified as needed, depending on the rate of a member’s weight loss. ABG procedures are laparoscopic only.
Laparoscopic loop or Mini-Gastric Bypass
Mini-Gastric Bypass works via restriction and malabsorption. The stomach is divided and a small tube of stomach is created which becomes the pouch. Then the surgeon brings up a loop of bowel and joins it to the lower part of the stomach pouch. The food passes from the stomach pouch into the small bowel where it meets the digestive juices which have moved downwards from the main part of the stomach. Thus, approximately 6 feet of small bowel has been bypassed before absorption of food (and calories) can take place, producing weight loss via fewer calories being absorbed.
Intragastric balloon systems are acid –resistant balloons that are inserted into the stomach via endoscope and then expanded with saline or air. The balloons occupy space and promote weight loss by creating a feeling of fullness which can lead to decreased food consumption. The device is in place for approximately 6 months before being retrieved.
Implantable gastric stimulators for treatment of obesity are intended to induce early satiety and thus limit intake through electrical stimulation of the gastric wall.
Transoral gastroplasty (TG) is a minimally invasive, incision-less, reversible weight-loss procedure in which the stomach size is restricted with staples or sutures by using endoscopic surgical tools guided through the mouth and esophagus into the stomach. Two examples of this procedure that are proposed for revisions of standard weight loss surgery are Stomaphyx and the ROSE procedure (restorative obesity surgery – endoluminal).
If available, codes are listed below for informational purposes only, and do not guarantee member coverage or provider reimbursement. The list may not be all-inclusive.
CPT Codes for procedures that are covered when they meet the above criteria:
Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and Roux-en-Y gastroenterostomy (roux limb 150 cm or less)
Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and small intestine reconstruction to limit absorption
Laparoscopy, surgical, gastric restrictive procedure; placement of adjustable gastric restrictive device (eg, gastric band and subcutaneous port components)
Laparoscopy, surgical, gastric restrictive procedure; revision of adjustable gastric restrictive device component only
Laparoscopy, surgical, gastric restrictive procedure; removal of adjustable gastric restrictive device component only
Laparoscopy, surgical, gastric restrictive procedure; removal and replacement of adjustable gastric restrictive device component only
Laparoscopy, surgical, gastric restrictive procedure; removal of adjustable gastric restrictive device and subcutaneous port components
Laparoscopy, surgical, gastric restrictive procedure; longitudinal gastrectomy (ie, sleeve gastrectomy
Gastric restrictive procedure, without gastric bypass, for morbid obesity;
vertical banded gastroplasty
Gastric restrictive procedure, without gastric bypass, for morbid obesity; other than vertical-banded gastroplasty
Gastric restrictive procedure with partial gastrectomy, pylorus-preserving duodenoileostomy and ileoileostomy (50 to 100 cm common channel) to limit absorption (biliopancreatic diversion with duodenal switch)
Gastric restrictive procedure, with gastric bypass for morbid obesity; with short limb (150 cm or less) Roux-en-Y gastroenterostomy
Gastric restrictive procedure, with gastric bypass for morbid obesity; with small intestine reconstruction to limit absorption
Revision, open, of gastric restrictive procedure for morbid obesity, other than adjustable gastric restrictive device (separate procedure)
Gastric restrictive procedure, open; revision of subcutaneous port component only
Gastric restrictive procedure, open; removal of subcutaneous port component only
Gastric restrictive procedure, open; removal and replacement of subcutaneous port component only
CPT Codes for procedures that may be covered when they meet the above criteria:
Unlisted laparoscopy procedure, stomach
Unlisted procedure, stomach
When used for weigh loss - Insertion or replacement of peripheral or gastric neurostimulator pulse generator or receiver, direct or inductive coupling (Note – this code may be covered for indications other than for weight loss).
Vagus nerve blocking therapy (morbid obesity); laparoscopic implantation of neurostimulator electrode array, anterior and posterior vagal trunks adjacent to esophagogastric junction (EGJ), with implantation of pulse generator, includes programming
Vagus nerve blocking therapy (morbid obesity); laparoscopic revision or replacement of vagal trunk neurostimulator electrode array, including connection to existing pulse generator
Vagus nerve blocking therapy (morbid obesity); laparoscopic removal of vagal trunk neurostimulator electrode array and pulse generator
Vagus nerve blocking therapy (morbid obesity); removal of pulse generator
Vagus nerve blocking therapy (morbid obesity); replacement of pulse generator
Vagus nerve blocking therapy (morbid obesity); neurostimulator pulse generator electronic analysis, includes reprogramming when performed
CPT Copyright American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association.
This information is for most, but not all, HealthPartners plans. Please read your plan documents to see if your plan has limits or will not cover some items. If there is a difference between this general information and your plan documents, your plan documents will be used to determine your coverage. These coverage criteria may not apply to Medicare Products if Medicare requires different coverage. For more information regarding Medicare coverage criteria or for a copy of a Medicare coverage policy, contact Member Services at 952-883-7979 or 1-800-233-9645.
- Adams, T., Davidson, L., Litwin, S., Kolotkin, R., LaMonte, M. Pendleton, R. …Hunt, S. (2012). Health Benefits of Gastric Bypass Surgery After 6 Years. Journal of the American Medical Association (JAMA), 308(11):1122-1131.
- American Academy of Sleep Medicine-Adult Obstructive Sleep Apnea Task Force (2009). Clinical Guideline for the Evaluation, Management and Long-term Care of Obstructive Sleep Apnea in Adults, Journal of Clinical Sleep Medicine, 5(3): 263-276.
- American Academy of Sleep Medicine Task Force (1999). Sleep –Related Breathing Disorders in Adults: Recommendations for Syndrome Definition and Measurement Techniques in Clinical Research, Sleep, 22(5):667-689.
- American Diabetes Association (2016). Standards of Medical Care in Diabetes- 2016, Diabetes Care-The Journal of Clinical and Applied Research and Education, 39(Suppl. 1): S1-S106.
- American Heart Association (2015). Treating Obesity as a Disease. Retrieved from http://www.heart.org, Sept, 2016.
- Calhoun, D., Jones, D., Textor, S., Goff, D., Murphy, T., Toto, R.,... Carey, R. (2008). Resistant Hypertension: Diagnosis, Evaluation, and Treatment. A Scientific Statement From the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation, 108. Retrieved from http://circ.ahajournals.org, March 2016.
- Courcoulas, A., Belle, S., Neiberg, R., Pierson, S., Eagleton, J., Kalachian, M., …Jakicic, J. (2015). Three-Year Outcomes of Bariatric Surgery vs Lifestyle Intervention for Type 2 Diabetes Mellitus Treatment- A Randomized Clinical Trial. JAMA Surgery 2015.1534. Retrieved from http://archsurg.jamanetwork.com, Oct, 2015.
- ECRI Institute. (2016). Intragastric Balloons for Treating Obesity. Plymouth Meeting, PA: ECRI Institute.
- ECRI Institute. (2015). Metabolic Surgery for Treating Type 2 Diabetes Mellitus Regardless of Patient BMI. Plymouth Meeting, PA: ECRI Institute.
- ECRI Institute. (2016). Rechargeable Vagal Blocking System (Maestro) for Treating Obesity. Plymouth Meeting, PA: ECRI Institute.
- Fitch, A., Everling L, Fox C, Goldberg J, Heim C, Johnson K, Kaufman T, Kennedy E, Kestenbaun C, Lano M, Leslie D, Newell T, O’Connor P, Slusarek B, Spaniol A, Stovitz S, Webb B. Institute for Clinical Systems Improvement. Prevention and Management of Obesity for Adults. Updated May 2013. Retrieved from http://www.icsi.org, Sept, 2016.
- Hayes, Inc. Hayes Medical Technology Directory Report. Comparative Effectiveness of Roux-en-Y and Sleeve Gastrectomy for Treatment of Type II Diabetes: A Review of Reviews. Lansdale, PA: Hayes, Inc.; July, 2017.
- Hayes, Inc. Directory. Intragastric Balloons for the Treatment of Obesity. Lansdale, PA. Hayes, Inc. March, 2016. Reviewed March, 2017.
- Hayes, Inc. Directory. Laparoscopic Bariatric Surgery: Roux-en-Y Gastric Bypass, Vertical Banded Gastroplasty and Adjustable Gastric Banding. Lansdale, PA: Hayes, Inc. June, 2007. Archived, 2012.
- Hayes, Inc. Directory. Roux-en-Y Gastric Bypass for Diabetes in Obese or Severely Obese Patients. Lansdale, PA: Hayes, Inc. Aug, 2014. Annual Review, Aug, 2016.
- Hayes, Inc. Directory. Roux-en-Y Gastric Bypass for Gastroesophageal Reflux Diesase in Obese or Severely Obese Patients. Lansdale, PA: Hayes, Inc. July, 2013. Annual Review, May, 2016.
- Hayes, Inc. Hayes Medical Technology Directory Report. Roux-en-Y Gastric Bypass for Treatment of Type II Diabetes: A Review of Reviews. Lansdale, PA: Hayes, Inc.; May, 2017.
- Hayes, Inc. Health Technology Brief. Maestro Rechargeable System (EnteroMedics Inc.) for Vagal Blocking for Obesity Control. Lansdale, PA: Hayes, Inc. Feb, 2016.
- Hayes, Inc. Subscriber Article. ReShape Integrated Dual Balloon System. Lansdale, PA: Hayes, Inc. Feb, 2016.
- Hsu, C., Almulaifi, A., Chen, J., Ser, K., Chen, S. Hsu, K. …Lee, W. (2015). Effect of Bariatric Surgery vs Medical Treatment on Type 2 Diabetes in Patients With Body Mass Index Lower Than 35- Five-Year Outcomes. JAMA Surgery 2015.2602. Retrieved from http://archsurg.jamanetwork.com, Oct, 2015.
- Institute for Clinical Systems Improvement (2014) Diabetes Mellitus in Adults, Type 2; Diagnosis and Management of- Clinical Guidelines. Retrieved from https://www.icsi.org/guidelines__more/catalog_guidelines_and_more/catalog_guidelines/catalog_endocrine_guidelines/diabetes/
- Lee, A. & Wall, M. Idiopathic intracranial hypertension (pseudotumor cerebri): Prognosis and Treatment. In: UpToDate, Brazis, P. (Ed) & Wilterdink, J. (Ed), UpToDate, Waltham, MA. (Accessed on Sept 27, 2016).
- Lim, R. Bariatric operations for management of obesity: Indications and pre-operative preparation. In: UpToDate, Jones, D. (Ed) & Chen, W. (Ed), UpToDate, Waltham, MA. (Accessed on Sept 27, 2016).
- McCulloch, D. Management of persistent hyperglycemia in type 2 diabetes mellitus. In: UpToDate, Nathan, D. (Ed) & Mulder, J. (Ed). UpToDate, Waltham, MA. (Accessed Sept 26, 2016).
- Rubino, F., Nathan, D. M., Eckel, R. H., Schauer, P. R., Alberti, K. G. M., Zimmet, P. Z., ... & Amiel, S. A. (2016). Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. Diabetes Care 39:861-877.
- Telem, D., Greenstein, A. & Wolfe, B. Medical outcomes following bariatric surgery. In: UpToDate, Jones, D. (Ed) & Chen, W. (Ed), UpToDate, Waltham, MA. (Accessed on Sept, 26, 2016).
- 01/01/2014 - Date of origin
- 11/01/2016 - Effective date